Su1146 BASAL LAYER TRANSCRIPTIONAL ALTERATIONS IN EARLY ESOPHAGEAL SQUAMOUS CELL CARCINOMA: UNVEILING SEX AND RISK FACTOR ASSOCIATIONS
Leggi →
Maggio 2024
Risultati per: Linee guida per la gestione del carcinoma basocellulare
Questo è quello che abbiamo trovato per te
Su1168 SERUM LEVELS OF TOTAL BILE ACIDS ARE ASSOCIATED WITH AN INCREASED RISK OF HEPATOCELLULAR CARCINOMA IN PATIENTS WITH CIRRHOSIS. A PROSPECTIVE COHORT STUDY
Leggi →
Maggio 2024
Su1276 CARBOPLATIN PLUS 5-FLUOROURACIL AS AN ALTERNATIVE FIRST-LINE PALLIATIVE TREATMENT FOR ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA: 11-YEAR EXPERIENCE FROM A TERTIARY HOSPITAL IN SOUTHERN THAILAND
Leggi →
Maggio 2024
Sa1241 NON-CANONICAL SPLICING OF PFKFB4 PROMOTES HEPATOCELLULAR CARCINOMA VIA DIRECT PHOSPHORYLATION OF AKT INDEPENDENT OF GLYCOLYSIS
Leggi →
Maggio 2024
Sa1230 NON-GENETICALLY REGULATED HETEROGENOUS GROWTH CAPACITY OF COLORECTAL ADENOMA CELLS IS IMPLICATED IN THE ADENOMA-CARCINOMA SEQUENCE
Leggi →
Maggio 2024
327 METHYLATION ANALYSIS OF RECURRENT HEPATOCELLULAR CARCINOMA
Leggi →
Maggio 2024
325 COMPARISON EFFICACY AND SAFETY BETWEEN ATEZOLIZUMAB PLUS BEVACIZUMAB AND LENVATINIB AS FIRST-LINE SYSTEMIC THERAPY FOR HEPATOCELLULAR CARCINOMA: A REAL-WORLD STUDY
Leggi →
Maggio 2024
Sa1032 A COMPREHENSIVE ANALYSIS OF HEPATOCELLULAR CARCINOMA MORTALITY IN THE UNITED STATES FOR 21 YEARS: A POPULATION-BASED TIME-TREND ANALYSIS
Leggi →
Maggio 2024
Sa1029 DISPARITIES IN HEPATOCELLULAR CARCINOMA SURVIVAL AND MORTALITY: A LARGE NATIONAL CANCER REGISTRY ANALYSIS IN THE UNITED STATES
Leggi →
Maggio 2024
Sa1557 EFFECTS OF METABOLIC RISK FACTORS ON THE RISK OF PROGRESSION TO CIRRHOSIS AND HEPATOCELLULAR CARCINOMA
Leggi →
Maggio 2024
326 GENOME-WIDE CRISPR-CAS9 SCREENING IN PATIENT-DERIVED HEPATOCELLULAR CARCINOMA ORGANOID IDENTIFIES ESSENTIAL AND LENVATINIB RESISTANCE-ASSOCIATED GENES
Leggi →
Maggio 2024
Su1105 SHIFTING AWAY FROM RACE-BASED GUIDELINES FOR SCREENING FOR HEPATOCELLULAR CARCINOMA IN PATIENTS WITH NON-CIRRHOTIC HBV
Leggi →
Maggio 2024
Sa1530 PERCENTAGE OF BACTEROIDES SPEICIES IN MICROBIOME AFFECT THERAPEUTIC EFFICACY OF IMMUNE CHECKPOINT INHIBITORS FOR HEPATOCELLULAR CARCINOMA.
Leggi →
Maggio 2024
1051 SODIUM-GLUCOSE COTRANSPORTER-2 INHIBITORS ASSOCIATED WITH LOWER RISK OF HEPATOCELLULAR CARCINOMA AND HEPATIC DECOMPENSATION IN TYPE 2 DIABETES MELLITUS
Leggi →
Maggio 2024
Mo1476 REGIONAL DIFFERENCE IN HEPATOCELLULAR CARCINOMA INCIDENCE TRENDS: A TWO-DECADE NATIONWIDE US ANALYSIS
Leggi →
Maggio 2024
687 PERFORMANCE AND NUTRITIONAL STATUS ARE EACH INDEPENDENTLY ASSOCIATED WITH SURVIVAL IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA RECEIVING IMMUNOTHERAPY
Leggi →
Maggio 2024
